drugset
drugset / Trial / NCT01433965

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT01433965 ↗

Phase 1 Completed 16 enrolled University of California, Davis Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be used to prevent the return of leukemia cells after a transplant.

Timeline

Start
2012-08-08
Primary completion
2018-06-12
Completion
2021-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 5 mg Oral
Subject Lenalidomide Other / unclassified 20 mg Oral

Indications

acute myeloid leukemia myelodysplastic syndrome